Alessandro M. Gianni
About
Alessandro M. Gianni is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology.
According to data from OpenAlex, Alessandro M. Gianni has authored 205 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 83 papers in Pathology and Forensic Medicine and 54 papers in Molecular Biology. Recurrent topics in Alessandro M. Gianni's work include Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Hematopoietic Stem Cell Transplantation (26 papers). Alessandro M. Gianni is often cited by papers focused on Lymphoma Diagnosis and Treatment (81 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Hematopoietic Stem Cell Transplantation (26 papers). Alessandro M. Gianni collaborates with scholars based in Italy, United States and Spain. Alessandro M. Gianni's co-authors include Massimo Di Nicola, Carmelo Carlo‐Stella, Michele Magni, Paola Matteucci, Marco Milanesi, Paolo Longoni, Salvatore Grisanti, Marco Bregni, Gianni Bonadonna and Salvatore Siena and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
In The Last Decade
Alessandro M. Gianni
199 papers receiving 9.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alessandro M. Gianni Italy | 44 | 3.7k | 3.4k | 3.1k | 2.1k | 2.1k | 205 | 9.4k | ||
| Paul J. Kurtin United States | 64 | 3.6k 1.0× | 2.8k 0.8× | 5.1k 1.6× | 2.2k 1.1× | 3.3k 1.6× | 235 | 11.4k | ||
| Carmelo Carlo‐Stella Italy | 40 | 3.0k 0.8× | 3.4k 1.0× | 1.9k 0.6× | 2.1k 1.0× | 2.4k 1.1× | 350 | 9.1k | ||
| Massimo Di Nicola Italy | 37 | 2.7k 0.7× | 2.9k 0.9× | 1.3k 0.4× | 2.1k 1.0× | 2.0k 1.0× | 160 | 7.5k | ||
| Wolfram Brugger Germany | 51 | 4.7k 1.3× | 1.9k 0.6× | 2.2k 0.7× | 3.7k 1.8× | 2.9k 1.4× | 191 | 10.6k | ||
| Felipe Samaniego United States | 47 | 3.2k 0.9× | 1.5k 0.4× | 3.1k 1.0× | 1.2k 0.6× | 2.1k 1.0× | 217 | 7.3k | ||
| Ulrich Dührsen Germany | 51 | 3.0k 0.8× | 3.3k 1.0× | 3.3k 1.0× | 3.2k 1.5× | 2.2k 1.1× | 283 | 10.3k | ||
| Izidore S. Lossos United States | 53 | 4.3k 1.2× | 2.5k 0.8× | 5.8k 1.9× | 2.8k 1.3× | 2.9k 1.4× | 353 | 10.8k | ||
| R. S. K. Chaganti United States | 60 | 3.6k 1.0× | 2.5k 0.7× | 3.7k 1.2× | 2.6k 1.3× | 6.7k 3.2× | 199 | 14.5k | ||
| Ioannis Anagnostopoulos Germany | 44 | 3.4k 0.9× | 1.1k 0.3× | 3.3k 1.1× | 2.3k 1.1× | 1.4k 0.7× | 136 | 7.8k | ||
| Lorenz Trümper Germany | 42 | 3.3k 0.9× | 2.1k 0.6× | 3.9k 1.2× | 1.6k 0.7× | 1.9k 0.9× | 203 | 7.5k |
Countries citing papers authored by Alessandro M. Gianni
Since
Specialization
Citations
This map shows the geographic impact of Alessandro M. Gianni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro M. Gianni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro M. Gianni more than expected).
Fields of papers citing papers by Alessandro M. Gianni
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alessandro M. Gianni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro M. Gianni. The network helps show where Alessandro M. Gianni may publish in the future.
Co-authorship network of co-authors of Alessandro M. Gianni
This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro M. Gianni. A scholar is included among the top collaborators of Alessandro M. Gianni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro M. Gianni. Alessandro M. Gianni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Figini, Mariangela, Marzia Pennati, Alessandro M. Gianni, et al.. (2020). Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. Cells. 9(10). 2231–2231.
2.
Rivoltini, Licia, Claudia Chiodoni, Paola Squarcina, et al.. (2016). TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. Clinical Cancer Research. 22(14). 3499–3512.
3.
Necchi, Andrea, Domenico Magazzù, Andrea Anichini, et al.. (2016). An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).. Journal of Clinical Oncology. 34(2_suppl). 480–480.
4.
Pedrazzoli, Paolo, Giovanni Martinelli, Alessandro M. Gianni, et al.. (2014). Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. Biology of Blood and Marrow Transplantation. 20(4). 501–506.
5.
Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2014). Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research. 20(22). 5641–5651.
6.
Zappasodi, Roberta, Marilena V. Iorio, Monica Tortoreto, et al.. (2014). Pleiotropic antitumor effects of the pan‐HDAC inhibitor ITF2357 against c‐Myc‐overexpressing human B‐cell non‐Hodgkin lymphomas. International Journal of Cancer. 135(9). 2034–2045.
7.
Rambaldi, Alessandro, Cristina Boschini, Giuseppe Gritti, et al.. (2013). The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy. American Journal of Hematology. 88(12). 1062–1067.
8.
Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2012). Phase II study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology. 158(1). 108–119.
9.
Tassi, Elena, Claudia Vegetti, Alessandra Molla, et al.. (2012). Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. Clinical Cancer Research. 18(12). 3316–3327.
10.
Necchi, Andrea, Nadia Zaffaroni, Luigi Mariani, et al.. (2012). Abstract LB-433: Biomarker analysis and final results of INT70/09 Phase II proof-of-concept study of Pazopanib (PZP) in refractory urothelial cancer (UC). Cancer Research. 72(8_Supplement). LB–433.
11.
Viviani, Simonetta, Pier Luigi Zinzani, Alessandro Rambaldi, et al.. (2011). ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. New England Journal of Medicine. 365(3). 203–212.
12.
Zappasodi, Roberta, Serenella M. Pupa, Gaia C. Ghedini, et al.. (2010). Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. Cancer Research. 70(22). 9062–9072.
13.
Lavazza, Cristiana, Carmelo Carlo‐Stella, Arianna Giacomini, et al.. (2010). Human CD34+ cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood. 115(11). 2231–2240.
14.
Devizzi, Liliana, Anna Guidetti, Corrado Tarella, et al.. (2008). High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. Journal of Clinical Oncology. 26(32). 5175–5182.
15.
Chiesa, Claudio, Francesca Botta, Angela Coliva, et al.. (2007). Dosimetry in Myeloablative 90 Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results. Cancer Biotherapy and Radiopharmaceuticals. 22(1). 113–120.
16.
Cortelazzo, Sergio, Michele Magni, Corrado Tarella, et al.. (2007). Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma. Blood. 110(11). 1282–1282.
17.
Devizzi, Liliana, Ettore Seregni, Anna Guidetti, et al.. (2006). High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.. Blood. 108(11). 3047–3047.
18.
Magni, Michele, Massimo Di Nicola, Carmelo Carlo‐Stella, et al.. (2002). Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. Leukemia Research. 26(12). 1131–1133.
19.
Bonfante, V., Simonetta Viviani, Liliana Devizzi, et al.. (2001). High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.. PubMed. 64. 51–5.
20.
Corradini, Paolo, Corrado Tarella, Marco Bregni, et al.. (2000). Allografting for patients with advanced hematological malignancies: non-myeloablative conditioning followed by the reinfusion of lymphocytes engineered with hsv thymidine kinase gene. Blood. 96.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul J. Kurtin Breakdown of academic impact, for papers by Carmelo Carlo‐Stella Breakdown of academic impact, for papers by Massimo Di Nicola Breakdown of academic impact, for papers by Wolfram Brugger Breakdown of academic impact, for papers by Felipe Samaniego Breakdown of academic impact, for papers by Ulrich Dührsen Breakdown of academic impact, for papers by Izidore S. Lossos Breakdown of academic impact, for papers by R. S. K. Chaganti Breakdown of academic impact, for papers by Ioannis Anagnostopoulos Breakdown of academic impact, for papers by Lorenz Trümper